InvestorsHub Logo
Post# of 252342
Next 10
Followers 833
Posts 119913
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 28401

Monday, 06/12/2006 9:10:09 AM

Monday, June 12, 2006 9:10:09 AM

Post# of 252342
RHEO to start over in AMD
(It was obvious they would have to.)

http://biz.yahoo.com/iw/060612/0134966.html

>>
OccuLogix Reports On Meeting With FDA

Monday June 12, 8:40 am ET
TORONTO, ONTARIO--(MARKET WIRE)--Jun 12, 2006 -- OccuLogix, Inc. (NasdaqNM: RHEO )(TSX:RHE.TO) today announced that representatives of the Company met with the U.S. Food and Drug Administration ("FDA") on June 8, 2006 to discuss the results of MIRA-1, the Company's recently completed clinical trial using its RHEO(TM) System to treat the dry form of age-related macular degeneration, and the impact those results will have on its application to market its RHEO(TM) System in the United States.

As expected, at the meeting, the FDA advised that it would require an additional study of the RHEO(TM) System to be performed. Accordingly, the Company expects to submit its application for an Investigational Device Exemption ("IDE") with a new protocol to the Agency within the next 60 days. Details of the new study will be released when the IDE is filed by the Company and accepted by the FDA.

Elias Vamvakas, OccuLogix's Chairman & CEO, commented, "We had a very positive and constructive meeting with the Agency and gained some valuable clarity on the regulatory pathway for the RHEO(TM) System. The FDA also indicated its willingness to allow the substitution of the new polysulfone Rheofilter(TM) for the older cellulose acetate filter in the upcoming study. This removes the regulatory uncertainties presented by making the substitution following FDA approval and eliminates the need to continue to build and maintain adequate inventories of the older filter in preparation for commercial launch."

About OccuLogix, Inc.

OccuLogix is a health care company that brings innovative and evidenced-based medical therapies to market. OccuLogix's common shares trade on the NASDAQ National Market under the symbol 'RHEO' and on the Toronto Stock Exchange under the symbol 'RHE'. Visit us on the internet at www.occulogix.com (corporate) and www.rheo.com (healthcare professionals, patients and caregivers).
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.